2.28

3.64% 0.08

Pre-market: 2.24 -0.04 -1.75%

Therapeuticsmd Inc (TXMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Therapeuticsmd Inc stock is traded at $2.28, with a volume of 118.72K. It is up +3.64% in the last 24 hours and up +14.00% over the past month. TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.

Previous Close:

$2.20

Open:

$2.2

24h Volume:

118.72K

Relative Volume:

3.45

Market Cap:

$26.39M

Revenue:

$3.35M

Net Income/Loss:

$86,000

P/E Ratio:

148.05

EPS:

0.0154

Net Cash Flow:

$2.67M

1W Performance:

+21.28%

1M Performance:

+14.00%

6M Performance:

+34.12%

1Y Performance:

+94.87%

1-Day Range:

$2.20

$2.42

1-Week Range:

$1.80

$2.42

52-Week Range:

$0.9811

$2.95

Therapeuticsmd Inc Stock (TXMD) Company Profile

Name

Therapeuticsmd Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

561-961-1900

Address

951 YAMATO ROAD, SUITE 220, BOCA RATON, FL

Employee

Twitter

@TherapeuticsMD

Next Earnings Date

2026-05-12

Latest SEC Filings

TXMD's Discussions on Twitter

Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXMD Therapeuticsmd Inc	2.28	26.39M	3.35M	86,000	2.67M	0.0154
TAK Takeda Pharmaceutical Co Adr	15.77	49.83B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.07	40.04B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.69	39.23B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	79.95	33.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.57	23.33B	3.17B	1.29B	1.01B	27.09

Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy
Apr-30-19	Resumed	Noble Capital Markets	Outperform
Jun-15-18	Initiated	JP Morgan	Overweight
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy
Dec-08-15	Reiterated	Jefferies	Buy
Dec-08-15	Reiterated	Stifel	Buy
Sep-21-15	Reiterated	Jefferies	Buy
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform
Apr-17-14	Reiterated	Noble Financial	Buy
Jan-28-14	Reiterated	Noble Financial	Buy

View All

Therapeuticsmd Inc Stock (TXMD) Latest News

Jun 15, 2026

TherapeuticsMD (TXMD) Gains 3.64%, Tests Resistance at $2.39High Low Breadth - newsline.com

Jun 15, 2026

Jun 14, 2026

TXMD Q3 2023 Earnings: EPS Misses Estimates Sharply, Yet Stock Surges 20.9%EPS Surprise History - newsline.com

Jun 14, 2026

Jun 12, 2026

TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch

Jun 12, 2026

Jun 11, 2026

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Jun 11, 2026

TXMD Q3 2023 Earnings: Wider-than-Expected Loss Highlights Operational ChallengesProfit Inflection Point - newsline.com

Jun 11, 2026

Jun 10, 2026

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Jun 10, 2026

TherapeuticsMD (TXMD) Nears Support Amid Modest Selling PressureIndex Put Call - newsline.com

Jun 10, 2026